STOCK TITAN

ASLAN Pharmaceuticals Ltd - ASLN STOCK NEWS

Welcome to our dedicated news page for ASLAN Pharmaceuticals (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ASLAN Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ASLAN Pharmaceuticals's position in the market.

Rhea-AI Summary
ASLAN Pharmaceuticals reports positive topline data from Phase 2b study of eblasakimab in atopic dermatitis; plans for Phase 3 development in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.5%
Tags
earnings
-
Rhea-AI Summary
ASLAN Pharmaceuticals will co-host a virtual investor event with a leading Clinical Research Organization (CRO) on the changing landscape of atopic dermatitis (AD) following Dupilumab's introduction. ASLAN will present additional analyses from the TREK-AD study and new market research on the AD treatment landscape. They will also discuss potential solutions for optimizing AD trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
clinical trial
-
Rhea-AI Summary
ASLAN Pharmaceuticals to present emerging data from the TREK-AD study and new market research on AD treatment landscape
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
clinical trial
Rhea-AI Summary
ASLAN Pharmaceuticals presents positive data from the Phase 2b TREK-AD study of eblasakimab in adults with moderate-to-severe atopic dermatitis at the 32nd EADV Congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.49%
Tags
clinical trial
-
Rhea-AI Summary
ASLAN Pharmaceuticals announces acceptance of four abstracts for presentation at the 32nd European Academy of Dermatology and Venereology Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
clinical trial
-
Rhea-AI Summary
ASLAN Pharmaceuticals to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
conferences
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq: ASLN) reported positive topline data from the TREK-AD Phase 2b study of eblasakimab, a potential first-in-class antibody, in treating atopic dermatitis. The data supports the advancement of eblasakimab into a Phase 3 clinical development program in 2024. The company also announced a strategic licensing agreement with Zenyaku Kogyo, a leading Japanese pharmaceutical company, for eblasakimab in Japan, providing an upfront payment of $12.0 million and potential milestones of up to $123.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
earnings
-
Rhea-AI Summary
ASLAN Pharmaceuticals announces positive topline data from Phase 2b study of eblasakimab in atopic dermatitis. The study showed competitive efficacy with once-monthly dosing, meeting primary and secondary endpoints. Eblasakimab demonstrated a rapid onset of action and was generally well-tolerated. Phase 3 program expected to start in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.41%
Tags
clinical trial
-
Rhea-AI Summary
ASLAN Pharmaceuticals will host a webcast to discuss the topline data from the global Phase 2b TREK-AD trial of eblasakimab in patients with moderate-to-severe atopic dermatitis on July 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.41%
Tags
conferences clinical trial
ASLAN Pharmaceuticals Ltd

Nasdaq:ASLN

ASLN Rankings

ASLN Stock Data

10.83M
370.17M
0.05%
14.9%
1.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Cayman Islands
190 Elgin Avenue

About ASLN

aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.